Perry David P 的 Form 4 申報
Better Therapeutics, Inc.BTTX，2021/11/1 申報
- 申報編號
- 0000899243-21-042250
- 申報時間
- 2021/11/1 20:55 ET
- 交易日
- 2021/4/30-10/28
- 申報延遲
- 185 天遲報
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 12 筆非衍生性交易、1 筆衍生性交易。公開市場買進合計 $251.2 萬。交易後 185 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Perry David PCIK 0001105941 | 董事、高階主管（見申報備註）、持股 10% 以上大股東 |
| David P. Perry 2015 TrustCIK 0001890678 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/4/30 | Common Stock | P買進取得 | +2,000 | $9.95 | +$19,900 | 2,000 | 直接 | |
| 2021/5/4 | Common Stock | P買進取得 | +3,476 | $9.93 | +$34,516.68 | 5,476 | 直接 | |
| 2021/5/13 | Common Stock | P買進取得 | +7,000 | $9.93 | +$69,510 | 12,476 | 直接 | |
| 2021/5/14 | Common Stock | P買進取得 | +3,060 | $9.93 | +$30,385.8 | 15,536 | 直接 | |
| 2021/5/21 | Common Stock | P買進取得 | +8,000 | $9.95 | +$79,600 | 23,536 | 直接 | |
| 2021/5/24 | Common Stock | P買進取得 | +8,000 | $9.94 | +$79,520 | 31,536 | 直接 | |
| 2021/5/26 | Common Stock | P買進取得 | +20,000 | $9.95 | +$199,000 | 51,536 | 直接 | |
| 2021/10/28 | Common Stock | A公司授予取得 | +10,164,015 | –F3,F4 | – | 10,215,551 | 間接 | |
| 2021/10/28 | Common Stock | A公司授予取得 | +293,150 | –F3,F4 | – | 10,508,701 | 間接 | |
| 2021/10/28 | Common Stock | A公司授予取得 | +21,336 | –F3,F4 | – | 10,530,037 | 間接 | |
| 2021/10/28 | Common Stock | P買進取得 | +200,000 | $10.00 | +$2,000,000 | 10,730,037 | 間接 | |
| 2021/10/28 | Common Stock | A公司授予取得 | +100,000 | $10.00 | +$1,000,000 | 10,830,037 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/10/28 | Common Stock | A公司授予取得 | +28,300 | $0.00 | $0 | 28,300 | 直接 | 重複申報 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F3
Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the "Merger Agreement"), by and among Mountain Crest Acquisition Corp. II ("Issuer"), MCAD Merger Sub Inc. ("Merger Sub") and Better Therapeutics, Inc. ("BTX"), on October 28, 2021, Merger Sub merged with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination").
表 I 有 3 筆交易的價格引用這則附註。
- F4
At the effective time of the Business Combination (the "Effective Time"), each share of BTX common stock (including shares of BTX common stock resulting from the conversion of BTX preferred stock and BTX Simple Agreements for Future Equity) was converted into a right to receive the number of shares of Issuer common stock equal to the product of the number of shares of BTX common stock and 0.9475 (the "Exchange Ratio"), with fractional shares rounded to the nearest whole share. Issuer subsequently changed its name to Better Therapeutics, Inc.
表 I 有 3 筆交易的價格引用這則附註。
備註
Executive Chairman of the Board of Directors